Xortx Therapeutics Inc.2025财年第一财季实现净利润-698673.00美元，同比增加76.87%

市场透视2025-05-25

5月25日，Xortx Therapeutics Inc.（XRTX.US）公布财报，公告显示公司2025财年第一财季净利润为-698673.00美元，同比增加76.87%；其中营业收入为0.00美元，每股基本收益为-0.19美元。从资产负债表来看，Xortx Therapeutics Inc.（XRTX.US）总负债757350.00美元，其中短期债务15662.00美元，资产负债比为0.01，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2538194866?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-25 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2538194866","market":"us","top_or_hot":-1,"title":"Xortx Therapeutics Inc.2025财年第一财季实现净利润-698673.00美元，同比增加76.87%","media":"市场透视","content":"<div>\n<p>5月25日，Xortx Therapeutics Inc.（XRTX.US）公布财报，公告显示公司2025财年第一财季净利润为-698673.00美元，同比增加76.87%；其中营业收入为0.00美元，每股基本收益为-0.19美元。从资产负债表来看，Xortx Therapeutics Inc.（XRTX.US）总负债757350.00美元，其中短期债务15662.00美元，资产负债比为0.01，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525000025a48af02b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xortx Therapeutics Inc.2025财年第一财季实现净利润-698673.00美元，同比增加76.87%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXortx Therapeutics Inc.2025财年第一财季实现净利润-698673.00美元，同比增加76.87%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-25 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525000025a48af02b&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月25日，Xortx Therapeutics Inc.（XRTX.US）公布财报，公告显示公司2025财年第一财季净利润为-698673.00美元，同比增加76.87%；其中营业收入为0.00美元，每股基本收益为-0.19美元。从资产负债表来看，Xortx Therapeutics Inc.（XRTX.US）总负债757350.00美元，其中短期债务15662.00美元，资产负债比为0.01，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525000025a48af02b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XRTX","symbol_name":"XORTX Therapeutics Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525000025a48af02b&s=b","article_id":"2538194866","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525000025a48af02b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2538194866","pubTimestamp":1748102417,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月25日，Xortx Therapeutics Inc.公布财报，公告显示公司2025财年第一财季净利润为-698673.00美元，同比增加76.87%；其中营业收入为0.00美元，每股基本收益为-0.19美元。从资产负债表来看，Xortx Therapeutics Inc.总负债757350.00美元，其中短期债务15662.00美元，资产负债比为0.01，流动比率为0.01。机构评级：截至2025年5月25日，当前有1家机构对Xortx Therapeutics Inc.目标价做出预测，其中目标均价为14.00美元，其中最低目标价为14.00美元，最高目标价为14.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"XRTX":"XORTX Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"Xortx Therapeutics Inc. achieved a net profit of-698,673.00 USD in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 76.87%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XRTX":0.9,"LENZ":1},"content_text":"5月25日，Xortx Therapeutics Inc.（XRTX.US）公布财报，公告显示公司2025财年第一财季净利润为-698673.00美元，同比增加76.87%；其中营业收入为0.00美元，每股基本收益为-0.19美元。从资产负债表来看，Xortx Therapeutics Inc.（XRTX.US）总负债757350.00美元，其中短期债务15662.00美元，资产负债比为0.01，流动比率为0.01。机构评级：截至2025年5月25日，当前有1家机构对Xortx Therapeutics Inc.目标价做出预测，其中目标均价为14.00美元，其中最低目标价为14.00美元，最高目标价为14.00美元。公司简介：XORTX Therapeutics Inc 是一家临床阶段的生物技术公司，专注识别、开发并可能商业化治疗由异常的嘌呤和尿酸代谢以及在罕见疾病指征如 ADPKD 和 T2DN 中的尿酸代谢调节的进行性肾脏疾病，以及与呼吸道病毒感染相关的急性肾损伤（AKI）的疗法。它的重点是开发三种治疗产品，以减缓或逆转慢性肾脏病的进展，解决面临与呼吸道病毒感染相关的 AKI 个体的迫切需求，并确定其他机会，利用现有和新的知识产权来解决健康问题。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2538194866","isCrawlerRequest":true}